Lars Grundemar serves as the Deputy Chief Executive Officer and Chief Medical Officer at AGB-Pharma AB since 2022 and is also an organizer for the Lund Spring Symposium, where Lars has been involved since the same year. Their governance experience includes positions as Director of the Board at ApoGlyx and AGB Development AB starting in 2023 and 2020, respectively. Additionally, Lars Grundemar is the Managing Director of In Manu Medici LG AB since 1993 and held the role of CEO and Chief Scientific Officer at Oncorena AB from 2017 to 2022. Their academic contributions include an ongoing position as Adjunct Professor at Lund University since 2014. Lars Grundemar has also served as Partner at Ventac Partners from 2018 to 2020 and as Chairman of the Board at Sinntaxis from 2018 to 2024, alongside a Directorship at Reccan AB from 2016 to 2020. Educational credentials include studies at Lund University and Cornell University, as well as training as a Registered Specialist in Clinical Pharmacology.
This person is not in the org chart
This person is not in any teams
This person is not in any offices